A number of new synthetic antifungal agents, including, in particular, the imidazoles and related azoles, have been developed in the last few years for use as oral or topical antifungal agents or both (1, 3, 7, 8, 10, 11) . There are three distinct groups of antifungal azoles: fused-ring imidazole compounds, the N-substituted (mono) imidazoles (4, 6) , and the N-substituted triazoles (11) Limited data now are available regarding the antifungal properties of R 51,211 (R 51,211, Basic Medical Information Brochure, Janssen Pharmaceutica, May 1983). In vitro, it is active against yeasts, dermatophytes, Aspergillusffumigatius, Sporothrix schenckii, and Phialophora verrucosa. Its halflife in humans is 11 to 15 h, with peak serum levels of 200 to 300 ng/ml obtained 2 to 3 h after a single 200-mg dose and with serum levels of 10 to 100 ng/ml persisting through 8 h. Clinically, it has been shown to be efficacious in humans in the treatment of pityriasis versicolor and vaginal candidiasis at dosages of 100 and 200 mg given once daily. This study reports on the comparison in vitro of R 51,211 with the topical agent Ro 14-4767/002 (Hoffmann-LaRoche Inc., Basel, Switzerland) (8, 11) and two orally active azoles: the triazole BAY n 7133 (Bayer AG, Wuppertal, Federal Republic of Germany) (3, 11) and ketoconazole (Janssen Pharmaceutica, Piscataway, N.J.).
MATERIALS AND METHODS Drugs. Four drugs were studied: ketoconazole (R 41,400; Janssen Pharmaceutica), BAY n 7133 (micronized, batch 744288; Bayer AG), Ro 14-4767/002 (Hoffmann-LaRoche Inc.), and R 51,211 (itraconazole; Janssen Pharmaceutica). MIC procedure. Kimmig agar (E. R. Merck, Federal Republic of Germany) supplemented with 0.5% glycerol,was used for the agar dilution method as previously described (1, 10, 11) . Serial dilutions of each drug (1,280 to 0.63 pug/ml) were prepared in 2-ml volumes of sterile saline. Molten Kimmig agar (18 ml) was added to each of the 2-ml drug concentrations. These mixtures were mixed and poured into sterile, square petri dishes (100 by 15 mm) and allowed to harden. Two drug-free plates of Kimmig agar (18 ml of agar plus 2 ml of saline) were added to each set of drug concentrations. In this way, each drug set contained 14 plates. Each set of plates for each drug was inoculated with the Steer replicator. One of the drug-free plates was inoculated at the beginning and the other at the end of the set. Plates were incubated at 300C for 2 May 1983) . Also, it has been shown that R 51,211 has curative effects at dosages of 2.5 to 10 mg/kg in experimentally disseminated trichophytosis and systemic candidiasis (12) . Thus, based on in vitro data presented here and the available preliminary in vivo data, R 51,211 appears to be a promising oral antifungal agent.
